CAR+ T Drug Development: The critical role of Flow Cytometry

Understand the vital role of Flow Cytometry in CAR+ T-cell clinical development. Access important insights into the two main types of Flow Cytometry assays, Flow Cytometry’s use in plasma cell immunophenotyping, the use and usefulness of minimal residual disease (MRD) assessments, and more.

Don’t miss these insights from Pharma Ignite, presented in partnership with Cerba Research.

Explore:

• The importance of Flow Cytometry in CAR+ T-cell clinical research
• The key aspects for assay development and validation when developing CAR+ T-cell clinical trials
• The added value of Flow Cytometry in multiple myeloma, minimal residual disease (MRD) assessments, and multiple myeloma phenotype
• CAR+ T-cell therapy: patient treatment, targeted antigens, and solutions for minimal residual disease (MRD) assessment and multiple myeloma phenotype assessment